Current Status of Angiotensin Receptor Blocker Recalls
https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.13955
WEBOct 21, 2019 · As of August 2019—more than a year after the recalls began—the information currently available from FDA indicates the detectability of nitrosamines remains to be determined for all losartan, irbesartan, azilsartan, and eprosartan products currently marketed in the United States. Download figure. Download PowerPoint. Figure 1.
DA: 41 PA: 28 MOZ Rank: 95 Up or Down: Up